##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 121 Download : 67

##plugins.themes.academic_pro.article.main##

Abstract

According to the WHO, this metabolic disease of the skeleton belongs to the leading non-infectious human pathologies after cardiovascular, oncological and diabetes mellitus. The article presents the results of studying the frequency of reducing bone mineral density and its relationship with traditional risk factors and clinical parameters, the effectiveness of the drug alfaphorcal (alfacalcidol) in complex treatment in 40 patients with systemic scleroderma with osteoporosis and osteopenia. According to ultrasound osteodensitometry, osteoporosis and osteopenia are a frequent complication of systemic scleroderma and are detected in 57.5% of patients. The incidence of osteoporosis in this disease is much higher with a long course of the disease and menopause. In patients with systemic scleroderma with osteoporosis, alfacalcidol at a dose of 0.5-1.0 μg per day leads to a significant reduction in bone pain, normalization of bone remodeling processes, and an increase in bone strength.

Keywords

patients osteoporosis bone mineral density vitamin D

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Masuda.B Kasimova, Khulkar B.Makhamatkhojaeva, Shakhlo B.Kakhkharova, & Mukhayyo. A. Akhmadjonova. (2022). The Drug Alphakalcidol Effectiveness in Osteoporosis in Patients with Systemic Sclerodermia. Texas Journal of Medical Science, 10, 71–75. https://doi.org/10.62480/tjms.2022.vol10.pp71-75
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Baranova I.A., Ershova O.B., Anaev E.Kh. Evaluation of the frequency and risk factors of low-energy skeletal fractures, according to a survey of patients with chronic inflammatory diseases. Results of a multicenter study of the Russian Association for Osteoporosis GLUCOST. //Osteoporosis and osteopathy. 2014; (3). C. 9-14. Baranova I.A., Yershova O.B., Anayev E.KH. i dr. Otsenka chastoty i faktorov riska nizkoenergeticheskikh perelomov skeleta, po dannym oprosa bol'nykh khronicheskimi vospalitel'nymi zabolevaniyami. Rezul'taty mnogotsentrovogo issledovaniya Rossiyskoy assotsiatsii po osteoporozu GLYUKOST. //Osteoporoz i osteopatii. 2014; (3). C. 9-14.
  2. Guseva N.G. Systemic scleroderma and pseudoscleroderma syndromes // - M.: Medicine, 1993. - C. 268. Guseva N.G. Sistemnaya sklerodermiya i psevdosklerodermicheskiye sin¬dromy // - M.: Meditsina, 1993. — C. 268.
  3. Dobrovolskaya O.V., Demin N.V., Smirnov A.V., Garzanova L.A., Toroptsova N.V., Alekperov R.T. Status of bone mineral density in patients with systemic scleroderma. Modern rheumatology. 2019; 13(1). C.58—63. Dobrovol'skaya O.V., Demin N.V., Smirnov A.V., Garzanova L.A., Toroptsova N.V., Alekperov R.T. Sostoyaniye mineral'noy plotnosti kosti u patsiyentov s sistemnoy sklerodermiyey. Sovremennaya revmatologiya. 2019; 13(1). C.58—63
  4. Dobrovolskaya O.V., Demin N.V., Smirnov A.V., Toroptsova N.V. The state of bone mineral density and the need for anti-osteoporotic therapy in postmenopausal women with systemic scleroderma. Medical advice. 2019; No. 9, pp. 72-79. Dobrovol'skaya O.V., Demin N.V., Smirnov A.V., Toroptsova N.V. Sostoyaniye mineral'noy plotnosti kostnoy tkani i potrebnost' v protivoosteoporoticheskoy terapii u zhenshchin v postmenopauze s sistemnoy sklerodermiyey. Meditsinskiy sovet. 2019; №9, C. 72-79.
  5. Ershova O.B., Anaev E.Kh., Anokhina T.N., Anoshkova O.N., Batyn S.Z. Evaluation of the frequency and risk factors of low-energy skeletal fractures according to a survey of patients with chronic inflammatory diseases. Results of a multicenter study of the Russian Association for Osteoporosis GLUCOST. Osteoporosis and osteopathy. 2014;17(3):9-14. Yershova O.B., Anayev E.KH., Anokhina T.N., Anoshenkova O.N., Batyn S.Z. i dr. Otsenka chastoty i faktorov riska nizkoenergeticheskikh perelomov skeleta po dannym oprosa bol'nykh khronicheskimi vospalitel'nymi zabolevaniyami. Rezul'taty mnogotsentrovogo issledovaniya rossiyskoy assotsiatsii po osteoporozu GLYUKOST. Osteoporoz i osteopatii. 2014;17(3):9-14.
  6. Nasonov E.L, editor. Russian clinical guidelines. Rheumatology. Moscow: GEOTAR-Media; 2017. 464 p. Nasonov E.L, editor. Russian clinical guidelines. Rheumatology. Moscow: GEOTAR-Media; 2017. 464 p.
  7. Balasubramanian A, Wade SW, Adler RA, et al. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. J Bone Miner Res. 2018 Oct;33(10):1881-1888. doi: 10.1002/jbmr.3523. Epub 2018 Aug 22.
  8. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008 Feb;37(4):223-35. Epub 2007 Aug 9. doi: 10.1016/j.semarthrit. 2007.05.003
  9. Omair MA, Pagnoux C, McDonald-Blumer H, Johnson SR. Low bone density in systemic sclerosis. A systematic review. //J Rheumatol. 2013 Nov;40(11):1881-90. doi: 10.3899/jrheum.130032. Epub 2013 Sep 15.